| scholarly article | Q13442814 |
| P2093 | author name string | Jorma Isola | |
| Minna Tanner | |||
| Katri Köninki | |||
| Mark Barok | |||
| P2860 | cites work | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 171-179 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Cancer Letters | Q326372 |
| P1476 | title | Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. | |
| P478 | volume | 306 |
| Q37013285 | An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer |
| Q54439772 | An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. |
| Q91622958 | Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma |
| Q38150774 | Biomarkers of drugs targeting HER-family signalling in cancer. |
| Q38408138 | Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand. |
| Q42704187 | CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models |
| Q55347137 | Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. |
| Q26774513 | Changing strategies for target therapy in gastric cancer |
| Q37131686 | Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q52581752 | Current therapeutic landscape for advanced gastroesophageal cancers. |
| Q92073891 | Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer |
| Q53681641 | Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. |
| Q39171471 | Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics |
| Q38210387 | HER2 directed therapy for gastric/esophageal cancers |
| Q26822730 | HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies |
| Q35211263 | HER2 in solid tumors: more than 10 years under the microscope; where are we now? |
| Q26746253 | HER2 testing in gastric cancer: An update |
| Q38151672 | HER2 therapies and gastric cancer: a step forward. |
| Q37644205 | Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy |
| Q47271330 | Improved Tumor Penetration and Single-Cell Targeting of Antibody Drug Conjugates Increases Anticancer Efficacy and Host Survival. |
| Q37998453 | Improving treatment of HER2-positive cancers: opportunities and challenges |
| Q26776198 | Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features |
| Q38221886 | Investigational therapies targeting the ErbB family in oesophagogastric cancer |
| Q54469155 | Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. |
| Q38812867 | Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms |
| Q91992316 | Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer |
| Q34655256 | Microtubule inhibitor-based antibody-drug conjugates for cancer therapy |
| Q38632917 | Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives |
| Q52599496 | Novel Systemic Therapies for Advanced Gastric Cancer. |
| Q36078581 | Oxidation Protection in Metal-Binding Peptide Motif and Its Application to Antibody for Site-Selective Conjugation |
| Q45361593 | Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer |
| Q37241496 | Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies |
| Q38666988 | Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. |
| Q33954595 | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. |
| Q47636102 | Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). |
| Q34008663 | RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer. |
| Q36273796 | Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products |
| Q38199128 | Recent advances and future trends in the targeted therapy of metastatic gastric cancer |
| Q34967104 | Recent advances in the HER2 targeted therapy of gastric cancer |
| Q37724647 | Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects |
| Q53178110 | SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. |
| Q34998509 | T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo |
| Q35027806 | T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. |
| Q41340207 | Targeted therapies for gastric cancer: failures and hopes from clinical trials |
| Q37341824 | Targeted therapy in gastric cancer. |
| Q37699264 | Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer |
| Q38633308 | Targeting HER 2 and angiogenesis in gastric cancer |
| Q38210070 | The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey |
| Q28078788 | The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond |
| Q38222585 | The role of targeted therapy for gastrointestinal tumors. |
| Q38417241 | Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer |
| Q38088038 | Trastuzumab emtansine in breast cancer |
| Q27853015 | Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance |
| Q33440401 | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study |
| Q38101890 | Trastuzumab emtansine: first global approval |
| Q33759627 | Trastuzumab emtansine: mechanisms of action and drug resistance |
| Q36220464 | Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer |
| Q35811043 | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells |
| Q28067696 | Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine? |
| Q39017073 | miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc |
Search more.